On March 10, 2023 Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) ("Miravo" or the "Company") reported that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced arrangement (the "Arrangement") with Searchlight Pharma Inc. (the "Purchaser") (Press release, Nuvo Pharmaceuticals, MAR 10, 2023, View Source [SID1234628545]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Arrangement is expected to close on or about Tuesday, March 14, 2023, subject to the satisfaction or waiver of all conditions to the Arrangement. Following completion of the Arrangement, the Company will be de-listed from the TSX and applications will be made for the Company to cease to be a reporting issuer in each of the provinces of Canada. Pursuant to the terms of the Arrangement, each holder of common shares in the capital of the Company (the "Company Shares") will receive $1.35 in cash, less applicable withholdings.

To receive the consideration under the Arrangement, each registered shareholder of the Company must complete, sign, date and return the letter of transmittal, which accompanied the Company’s management information circular dated February 6, 2023.

The consideration to be paid to the Company’s shareholders under the Arrangement is denominated in Canadian dollars. However, registered shareholders of the Company may elect to receive the consideration in U.S. dollars in the applicable letter of transmittal. Non-registered shareholders of the Company must contact the intermediary in whose name their Company Shares are registered in order to make such an election on their behalf.

On March 10, 2023 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported that on March 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 250,300 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan") (Press release, Crinetics Pharmaceuticals, MAR 10, 2023, View Source [SID1234628540]). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $17.28 per share, which is equal to the closing price of Crinetics’ common stock on The Nasdaq Global Select Market on March 10, 2023. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee’s continued employment with Crinetics on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

On March 10, 2023 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, reported that new data supporting its portfolio of skin cancer gene expression profile (GEP) tests will be showcased in one late-breaking oral presentation and three ePosters at the 2023 American Academy of Dermatology (AAD) Annual Meeting, being held March 17-21 in New Orleans (Press release, Castle Biosciences, MAR 10, 2023, View Source [SID1234628531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Castle, we believe our tests help clinicians make more informed decisions in the care of patients with skin cancers," said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. "As such, we focus strongly on continued evidence development to demonstrate where our tests can add value to clinical decision-making to improve outcomes for patients. In collaboration with leading physicians across the U.S., we are proud to present new data at this year’s AAD meeting highlighting the utility of our dermatologic tests as part of our commitment to advancing patient care."

Following are details for the four abstracts that were accepted at AAD. Abstract content for the ePosters will be available in the online viewing portal beginning the first day of the meeting and on-site using the computers at the Poster Exhibit Presentation Center. They will also be published online via the JAAD supplement in Fall 2023.

DecisionDx-SCC
Late-breaking oral presentation title: The 40-gene expression profile (40-GEP) continues to demonstrate independent metastatic risk stratification and improved accuracy in risk assessment in a novel cohort of cutaneous squamous cell carcinoma (cSCC) patients with one or more risk factors
Presenter and Lead Author: Ashley Wysong, M.D., M.S., Department of Dermatology, University of Nebraska Medical Center
Date: March 18, 2023
Time: 3:40-3:50 p.m. Central time
Location: New Orleans Ernest N. Morial Convention Center, Theater B

ePoster title: Clinicians’ use of the 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (SCC) patients is consistent with intended use parameters
Lead Author: Gaurav Singh, M.D., Milwaukee
Abstract Number: 44006

DecisionDx-Melanoma
ePoster title: The 31-gene expression profile test for cutaneous melanoma identifies patients with stage IB-IIA disease who have recurrence risk similar to that of stage IIB-IIC disease
Lead Author: Abel Jarell, M.D., Northeast Dermatology Associates, P.C., Portsmouth, New Hampshire
Abstract Number: 43858

MyPath Melanoma
ePoster title: Diagnostic discordance among histopathological reviewers for difficult-to-diagnose melanocytic lesions
Lead Author: Matthew Goldberg, M.D., Castle Biosciences and Icahn School of Medicine at Mount Sinai, New York
Abstract Number: 42072

About DecisionDx-SCC

DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1 (low), 2A (moderate) or 2B (high) risk category, predicts individual metastatic risk to inform risk-appropriate management.

Peer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.

About DecisionDx-Melanoma

DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient’s personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by more than 40 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through Dec. 31, 2022, DecisionDx-Melanoma has been ordered 120,287 times for patients diagnosed with cutaneous melanoma.

About MyPath Melanoma

MyPath Melanoma is Castle’s gene expression profile test designed to provide an accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions. Of the approximately two million suspicious pigmented lesions biopsied annually in the U.S., Castle estimates that approximately 300,000 of those cannot be confidently classified as either benign or malignant through traditional histopathology methods. For these cases, the treatment plan can also be uncertain. Obtaining accurate, objective ancillary testing can mean the difference between a path of overtreatment or the risk of undertreatment. Interpreted in the context of other clinical, laboratory and histopathologic information, MyPath Melanoma is designed to reduce uncertainty and provide confidence for dermatopathologists and help dermatologists deliver more informed patient management plans.

On March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, reported that its management team will attend and take part in 1-on-1 meetings with potential business partners at the following meetings (Press release, Enterome, MAR 10, 2023, View Source [SID1234628527])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• Glioblastoma Drug Development Summit – March 14-16 in Boston (MA), US
• BIO-Europe Spring – March 20-22 in Basel, Switzerland
• MATWIN’s MEET2WIN – May 11-12 in Bordeaux, France

Enterome’s CEO, Pierre Belichard, will present an overview of the Company and take part in 1-
on-1 meetings with potential investors at the following conferences:
• BioTrinity 2023 – April 25-26 in London, UK
• Bio€quity Europe 2023 – May 14-16 in Dublin, Ireland

On March 10, 2023 Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, reported that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023 (Press release, Kiromic, MAR 10, 2023, View Source [SID1234628526]). Kiromic common stock will begin trading on a split-adjusted basis when the market opens on March 13, 2023 under the existing trading symbol KRBP. As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 497634204. The reverse stock split was previously approved by Kiromic stockholders at the Special Meeting of Stockholders held on March 7, 2023, with the final ratio determined by the Company’s Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Upon effectiveness of the reverse stock split, every 30 shares of Kiromic common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock. Outstanding equity-based awards and other outstanding equity rights will be proportionately adjusted. No fractional shares will be issued as a result of the reverse stock split. Immediately after the reverse stock split becomes effective, the Company will have approximately 966,758 shares of common stock issued and outstanding. Stockholders of record otherwise entitled to receive a fractional share as a result of the reverse stock split will automatically be entitled to receive an additional fraction of a share of common stock to round up to the next whole share.

The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement.

"In addition to regaining compliance with Nasdaq’s continued-listing requirements, our shareholder-approved reverse stock split may make our stock more attractive to institutional investors and other members of the investing public, thereby providing for a stronger and more diverse investor base," commented Pietro Bersani, Chief Executive Officer of Kiromic.

Additional information concerning the reverse stock split can be found in Kiromic’s definitive proxy statement filed with the Securities and Exchange Commission on January 25, 2023.